Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
|Articles|May 8, 2021
CURE Honors World Ovarian Cancer Day
Author(s)Jessica Skarzynski
Today is World Ovarian Cancer Day, and in honor of this day that was created in 2013 to raise awareness about the disease, CURE® is rounding up the latest news and updates in this cancer space.
Advertisement
In honor of World Ovarian Cancer Day, which was created in 2013 to raise awareness about the disease, CURE® rounded up the latest news and updates in this cancer space:
- Despite on-treatment clinical progression, patients
treated with Avastin (bevacizumab) and standard chemotherapy had a median progression-free survival of 11.8 months compared with 8.8 months in those treated with standard chemotherapy alone.
- In this episode of the “CURE® Talks Cancer” podcast, we spoke with an
ovarian cancer survivor and teacher about how she maintained her sense of humor through treatment and why it’s important to remain connected to friends and family, especially during the darkest moments.
- Following
chemotherapy with secondary cytoreduction for patients with platinum-sensitive relapsed ovarian cancer contributed to longer progression-free survival compared with chemotherapy alone, according to study results published in The Lancet Oncology.
Maintenance therapy with a PARP inhibitor demonstrated benefits including progression-free survival for those with high-grade, recurrent, platinum-sensitive ovarian cancer, according to data published in Cancer.
- Fertility treatments led to an ovarian cancer diagnosis but also opened the door to adoption and a new view on life for
Elizabeth Johnston , who shared her story with us in our latest Women’s Cancers Special Issue.
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.
For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
4
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
5